At IMMUNOSTEP we develop innovative solutions in order to help improving research and diagnosis performance in key areas of development.
We will continue to work every day to deliver high-quality technology in order to fight against the global health emergency by assuring reliable results.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus that belongs to the family of coronaviruses, of the genus Betacoronavirus, which emerged in China in the city of Wuhan, Hubei province in December 2019 and was It has spread throughout the world until being declared by WHO as a pandemic in March 2020.
In response to the Covid-19 pandemic, CSIC research groups have worked in collaboration with Immunostep to develop these serological tests capable of detecting specific SARS-CoV-2 antibodies and monitoring immune responses with an estimated accuracy close to 100%.
Indirect Enzyme Immunoassay for detection of IgG antibodies against Mpro specific protein of SARS-CoV-2
Indirect Enzyme Immunoassay for detection of IgA antibodies against Mpro specific protein of SARS-CoV-2
Indirect Enzyme Immunoassay for the detection of IgG antibodies against Spike protein of SARS-CoV-2.
Indirect Enzyme Immunoassay for detection of IgA antibodies against Spike protein of SARS-CoV-2
Detecting SARS-CoV-2 immune response with an accuracy close to 100%.
High sensitivity and specifity targeting highly antigenic structural and non-structural proteins.
Very early antibody detection from the symptoms onset identifying IgG, IgA and IgM immunoglobulins.
We work everyday to improve serology testing performance by innovating and adapting new technology to collaborate building meaningful clinical investigation.
CE/IVD kits are only suitable for clinical use in European Union and countries with EU conformity recognition agreements. Manufactured in Spain by Immunostep under CSIC Patent License.